Company: CMND
Filing Date: 2025-09-15
Form Type: POS AM
Source: 0001213900-25-087398
Chunk: 10

Company: Clearmind Medicine Inc.
Filing Date: 2025-09-15
Form: POS AM
Chunk 10
---
ating DIO-induced hyperglycemia, glucose intolerance, and hyperinsulinemia; (iii) reduced DIO-induced hepatic steatosis
by decreasing hepatic lipid accumulation and lowered liver triglyceride and cholesterol levels, primarily by inhibiting de novo lipid
synthesis, and demonstrating that metabolic phenotyping revealed that MEAI increased energy expenditure and fat utilization while maintaining
food consumption similar to that of the vehicle-treated group; and (iv) normalized voluntary locomotion actions without any over stimulatory
effects. These findings provided compelling evidence for the anti-obesity effects of MEAI treatment and highlighted the potential of
MEAI as a novel therapeutic approach for treating obesity and its associated metabolic disorders, offering hope for the development of
new treatment options for this global health challenge.

‍
Additionally, we have engaged Professor Gal Yadid from the Gonda Multidisciplinary Brain
Research Center located at Bar Ilan University (Ramat Gan, Israel) to advance the evaluation
of MEAI as a potential treatment for addictions and other binge behaviors. Prof. Yadid, a
prominent figure in the research and development of treatments for psychiatric disease, specifically
drug addiction, depression, and PTSD, and his team conducted a series of studies to explore
the mechanism of action and specific neural targets of MEAI to evaluate its efficacy as a
potential therapeutic agent in the treatment of addiction and related behaviors. The results
of pre-clinical research studies suggested that MEAI may be effective in the treatment of
substance addiction and specifically cocaine without interrupting the natural reward process.
According to the United Nations Office on Drugs and Crime’s “2022 World Drug
Report”, of the estimated 284 million people who had used drugs in the past year, approximately
13.6%, 38.6 million, are estimated to have suffered from drug use disorders. While some addictions,
such as drugs and alcohol, are more concerning than others, addiction and compulsive behavior
is not limited to these substances. Compulsive consumption of food, shopping, gambling, sex,
television, and technology, many of which increased in prevalence during the recent pandemic,
can all be destructive when their use cannot be managed and all can potentially be treated
by MEAI.

Corporate Information

We were incorporated under the name Cyntar Ventures
Inc. on July 18, 2017, pursuant to the provisions of the Business Corporations Act(British Columbia). On March 24,
2021, we changed our name